Protocol Ledger

NCT07389265 · Phase III · RECRUITING

Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer

Interventional Phase III clinical trial protocol NCT07389265 sponsored by University of Campania Luigi Vanvitelli in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-10-01 Enrollment: 480 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07389265
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)480 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07389265
Protocol FieldVerified Registry Value
NCT IdentifierNCT07389265
Consolidated Lead SponsorUniversity of Campania Luigi Vanvitelli
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment480 participants (ESTIMATED)
Registered Start Date2025-10-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07389265
Hospital Research SiteLocationSite Profile
ASST Grande Ospedale Metropolitano NiguardaMilan, ItalyOpen Hospital Dossier ->
Fondazione IRCCS Istituto Nazionale dei TumoriMilan, ItalyOpen Hospital Dossier ->
Istituto Europeo di OncologiaMilan, ItalyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI